The prognostic value of CT radiomic features for patients with pulmonary adenocarcinoma treated with EGFR tyrosine kinase inhibitors

Serum Neuron-Specific Enolase Levels Predict the Efficacy of First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations

(2016) Koung Jin Suh et al.   Clinical Lung Cancer

Temporal Changes of Texture Features Extracted From Pulmonary Nodules on Dynamic Contrast-Enhanced Chest Computed Tomography

(2016) Hyungjin Kim et al.   INVESTIGATIVE RADIOLOGY

Stage III Non–Small Cell Lung Cancer: Prognostic Value of FDG PET Quantitative Imaging Features Combined with Clinical Prognostic Factors

(2016) David V. Fried et al.   RADIOLOGY

Quantitative Features of Liver Lesions, Lung Nodules, and Renal Stones at Multi–Detector Row CT Examinations: Dependency on Radiation Dose and Reconstruction Algorithm

(2016) Justin Solomon et al.   RADIOLOGY

Tumor Heterogeneity in Lung Cancer: Assessment with Dynamic Contrast-enhanced MR Imaging

(2016) Soon Ho Yoon et al.   RADIOLOGY

Radiomics Signature: A Potential Biomarker for the Prediction of Disease-Free Survival in Early-Stage (I or II) Non—Small Cell Lung Cancer

(2016) Yanqi Huang et al.   RADIOLOGY

Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study

(2016) Ji Hyun Lee et al.   CANCER IMAGING

Reproducibility of radiomics for deciphering tumor phenotype with imaging

(2016) Binsheng Zhao et al.   Scientific Reports

Detection of T790M, the Acquired Resistance EGFR Mutation, by Tumor Biopsy versus Noninvasive Blood-Based Analyses

(2015) T. K. Sundaresan et al.   CLINICAL CANCER RESEARCH

Preliminary investigation into sources of uncertainty in quantitative imaging features

(2015) Xenia Fave et al.   COMPUTERIZED MEDICAL IMAGING AND GRAPHICS

Prognostic potential of initial CT changes for progression-free survival in gefitinib-treated patients with advanced adenocarcinoma of the lung: a preliminary analysis

(2015) Yu-Cheng Wu et al.   EUROPEAN RADIOLOGY

Measuring Computed Tomography Scanner Variability of Radiomics Features

(2015) Dennis Mackin et al.   INVESTIGATIVE RADIOLOGY

Prognostic Value of Computed Tomography Texture Features in Non–Small Cell Lung Cancers Treated With Definitive Concomitant Chemoradiotherapy

(2015) Su Yeon Ahn et al.   INVESTIGATIVE RADIOLOGY

Total Lesion Glycolysis in Positron Emission Tomography Can Predict Gefitinib Outcomes in Non–Small-Cell Lung Cancer with Activating EGFR Mutation

(2015) Bhumsuk Keam et al.   Journal of Thoracic Oncology

Non–Small Cell Lung Cancer Treated with Erlotinib: Heterogeneity of18F-FDG Uptake at PET—Association with Treatment Response and Prognosis

(2015) Gary J. R. Cook et al.   RADIOLOGY

Pemetrexed Singlet Versus Nonpemetrexed-Based Platinum Doublet as Second-Line Chemotherapy after First-Line Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Failure in Non-small Cell Lung Cancer Patients with EGFR Mutations

(2015) Sehhoon Park et al.   Cancer Research and Treatment

Survival Outcome Assessed According to Tumor Response and Shrinkage Pattern in Patients with EGFR Mutation–Positive Non–Small-Cell Lung Cancer Treated with Gefitinib or Erlotinib

(2014) Masayuki Takeda et al.   Journal of Thoracic Oncology

Volume and Mass Doubling Times of Persistent Pulmonary Subsolid Nodules Detected in Patients without Known Malignancy

(2014) Yong Sub Song et al.   RADIOLOGY

Computerized Texture Analysis of Persistent Part-Solid Ground-Glass Nodules: Differentiation of Preinvasive Lesions from Invasive Pulmonary Adenocarcinomas

(2014) Hee-Dong Chae et al.   RADIOLOGY

Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

(2014) Bhumsuk Keam et al.   Cancer Research and Treatment

Tumor Heterogeneity and Permeability as Measured on the CT Component of PET/CT Predict Survival in Patients with Non-Small Cell Lung Cancer

(2013) T. Win et al.   CLINICAL CANCER RESEARCH

Texture analysis of advanced non-small cell lung cancer (NSCLC) on contrast-enhanced computed tomography: prediction of the response to the first-line chemotherapy

(2013) Marco Ravanelli et al.   EUROPEAN RADIOLOGY

Tumor Volume Decrease at 8 Weeks Is Associated with Longer Survival in EGFR-Mutant Advanced Non–Small-Cell Lung Cancer Patients Treated with EGFR TKI

(2013) Mizuki Nishino et al.   Journal of Thoracic Oncology

Prognostic Impact of [18F]Fluorothymidine and [18F]Fluoro-D-Glucose Baseline Uptakes in Patients with Lung Cancer Treated First-Line with Erlotinib

(2013) Matthias Scheffler et al.   PLoS One

Defining shape measures for 3D star-shaped particles: Sphericity, roundness, and dimensions

(2013) Jeffrey W. Bullard et al.   POWDER TECHNOLOGY

How Molecular Understanding Affects to Prescribing Patterns and Clinical Outcome of Gefitinib in Non-small Cell Lung Cancer? 10 Year Experience of Single Institution

(2013) Bhumsuk Keam et al.   Cancer Research and Treatment

Cutoff Finder: A Comprehensive and Straightforward Web Application Enabling Rapid Biomarker Cutoff Optimization

(2012) Jan Budczies et al.   PLoS One

Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival

(2011) Balaji Ganeshan et al.   EUROPEAN RADIOLOGY

Early Prediction of Nonprogression in Advanced Non–Small-Cell Lung Cancer Treated With Erlotinib By Using [18F]Fluorodeoxyglucose and [18F]Fluorothymidine Positron Emission Tomography

(2011) Thomas Zander et al.   JOURNAL OF CLINICAL ONCOLOGY

18F-FDG PET/CT for Monitoring Treatment Responses to the Epidermal Growth Factor Receptor Inhibitor Erlotinib

(2011) M. R. Benz et al.   JOURNAL OF NUCLEAR MEDICINE

Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study

(2011) Caicun Zhou et al.   LANCET ONCOLOGY

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER